What Researchers Did
Researchers studied patients with sudden hearing loss in one ear to see whether hyperbaric oxygen therapy (HBOT) changes levels of two proteins in the blood that are linked to hearing recovery.
What They Found
This clinical study found that patients with moderately severe to profound sudden sensorineural hearing loss had lower blood levels of IGF-1 and HSP70 than healthy people before treatment. After treatment, both proteins rose in patients who received HBOT plus medical therapy and in patients who received medical therapy alone, but the increase was significantly higher in the group that also received HBOT. The abstract does not report the exact patient count, hearing gain in decibels, or specific percentage outcomes, so those figures cannot be stated here.
What This Means for Canadian Patients
For patients with sudden hearing loss in one ear, this study suggests that adding HBOT to standard medical therapy may support hearing recovery more than medical therapy alone, tied to bigger increases in IGF-1 and HSP70. The abstract frames HBOT as already recommended for initial and salvage treatment of this condition, though it notes the underlying mechanism was previously unclear.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The abstract does not report the total number of patients enrolled or the exact statistical values for the group comparisons, which limits how precisely the size of the benefit can be judged.